Developer docs
API playgroundTry for free, no card

Search company profiles

Alvine Pharmaceuticals

Full company profile

uuid000bzfj

Namestring
Alvine Pharmaceuticals
Legal namestring
CANDU123.COM
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Alvine Pharmaceuticals is a privately held clinical-stage biotechnology company founded in 2005 and headquartered in San Carlos, California. Per the input data, the company develops therapeutics for autoimmune and inflammatory diseases, with operations supported by 11-50 employees. Scientific direction is anchored by founder Chaitan S. Khosla, a Stanford-based scientist, complemented by a board of directors that includes Bill Ringo, Patrick Gage, David Schnell, and Michael Powell.

The firm has deployed a venture-backed biotech business model, raising approximately $68 million across five financing rounds between 2006 and 2013. Capital was sourced from a syndicate of biotech-focused investors including Sofinnova Investments, Flagship Pioneering, InterWest Partners, Black River Asset Management, Panorama Capital, and Prospect Venture Partners, with Sofinnova and Prospect co-leading earlier rounds. The largest single financing was a $26.5M round in March 2011, followed by two $6M follow-on financings in October 2011 and January 2013, suggesting a transition to bridge/extension financing in the company's most recent visible capital activity.

The input data does not enumerate specific drug candidates, clinical-stage assets, indications under development, partnerships, licensing arrangements, or revenue figures. Consequently, the company's commercial mechanism, pricing model, and product-level technical architecture cannot be characterized from the source material. The post-2013 silence in the data is a material caveat for any forward-looking assessment.

Short descriptiontext

Alvine Pharmaceuticals is a San Carlos, California-based private biotechnology company founded in 2005 that develops therapeutics for autoimmune and inflammatory diseases, backed by Sofinnova, Flagship Pioneering, and InterWest Partners across venture rounds totaling approximately $68 million.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Carlos, United States
HQ citystring
San Carlos
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
autoimmune disease therapeutics, inflammatory disease therapies, biopharmaceutical development, clinical-stage biotechnology, protein therapeutics
Industry4 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Immunology Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alvine Pharmaceuticals is a biotechnology company developing therapeutics for autoimmune and inflammatory diseases. The company focuses on protein-based drug candidates targeting conditions in immunology, with operations based in San Carlos, United States, and was founded in 2005.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No information available about Alvine Pharmaceuticals products and services.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Co-marketer of Dupixent, a flagship autoimmune/inflammation biologic. Comparable peer given its leadership position in immunology and ongoing M&A in the space.

TypeBroad incumbent
Description

Global immunology leader anchored by Humira and Skyrizi/Rinvoq. Comparable to Alvine as a major developer and commercializer of autoimmune/inflammatory therapeutics, though far broader in scope and scale.

TypeBroad incumbent
Description

Large-cap biotech with a significant inflammation/autoimmune franchise (e.g., Enbrel, Otezla). Relevant incumbent peer given overlapping therapeutic focus and biologic modality.

TypeBroad incumbent
Description

Janssen's immunology unit markets Stelara, Tremfya, and Remicade. Comparable as a leading commercializer of autoimmune biologics with deep pipeline investment.

TypeBroad incumbent
Description

Developer of Dupixent and other inflammation biologics. Comparable as a biologics-driven company with a strong autoimmune/inflammation franchise and pipeline.

6Bristol-Myers Squibb
TypeBroad incumbent
Description

Owns Zeposia and other immunology assets. Comparable as a major player with significant autoimmune/inflammation R&D and commercial presence.

TypeBroad incumbent
Description

Mid-to-large biotech expanding from cystic fibrosis into autoimmune and inflammatory diseases (e.g., VX-548, JAK programs). Comparable as a science-driven biotech with growing autoimmune ambitions.

TypeEmerging player
Description

Clinical-stage biotech developing antibody therapeutics for inflammation and autoimmune disease. Comparable as a focused autoimmune-focused biotech at a similar development stage.

9ChemoCentryx
TypeEmerging player
Description

Autoimmune-focused biotech (acquired by Amgen in 2022) that developed Tavalisse and Tavneos. Comparable as a small-cap autoimmune specialist eventually absorbed by a larger player — a plausible Alvine outcome.

TypeEmerging player
Description

Clinical-stage biotech developing peptide-based therapeutics for autoimmune and inflammatory diseases. Comparable given similar size, modality innovation, and therapeutic area focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alvine Pharmaceuticals

Immunology Therapeuticsalvinepharma.com

Alvine Pharmaceuticals is a San Carlos, California-based private biotechnology company founded in 2005 that develops therapeutics for autoimmune and inflammatory diseases, backed by Sofinnova, Flagship Pioneering, and InterWest Partners across venture rounds totaling approximately $68 million.

What Alvine Pharmaceuticals does

Alvine Pharmaceuticals is a privately held clinical-stage biotechnology company founded in 2005 and headquartered in San Carlos, California. Per the input data, the company develops therapeutics for autoimmune and inflammatory diseases, with operations supported by 11-50 employees. Scientific direction is anchored by founder Chaitan S. Khosla, a Stanford-based scientist, complemented by a board of directors that includes Bill Ringo, Patrick Gage, David Schnell, and Michael Powell.

The firm has deployed a venture-backed biotech business model, raising approximately $68 million across five financing rounds between 2006 and 2013. Capital was sourced from a syndicate of biotech-focused investors including Sofinnova Investments, Flagship Pioneering, InterWest Partners, Black River Asset Management, Panorama Capital, and Prospect Venture Partners, with Sofinnova and Prospect co-leading earlier rounds. The largest single financing was a $26.5M round in March 2011, followed by two $6M follow-on financings in October 2011 and January 2013, suggesting a transition to bridge/extension financing in the company's most recent visible capital activity.

The input data does not enumerate specific drug candidates, clinical-stage assets, indications under development, partnerships, licensing arrangements, or revenue figures. Consequently, the company's commercial mechanism, pricing model, and product-level technical architecture cannot be characterized from the source material. The post-2013 silence in the data is a material caveat for any forward-looking assessment.

Alvine Pharmaceuticals firmographics

Firmographics
Name
Alvine Pharmaceuticals
Legal name
CANDU123.COM
Website
https://alvinepharma.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Alvine Pharmaceuticals is a San Carlos, California-based private biotechnology company founded in 2005 that develops therapeutics for autoimmune and inflammatory diseases, backed by Sofinnova, Flagship Pioneering, and InterWest Partners across venture rounds totaling approximately $68 million.
Ownership category
akta.pro rank

Alvine Pharmaceuticals industry classification

Industry
Product category
Immunology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Autoimmune disease therapeutics
  • Inflammatory disease therapies
  • Biopharmaceutical development
  • Clinical-stage biotechnology
  • Protein therapeutics

Where Alvine Pharmaceuticals is headquartered

Location

Headquarters

HQ city
San Carlos
HQ country
United States
HQ region
North America

Markets served

Alvine Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Alvine Pharmaceuticals product offering

Product offering

Core offering

Alvine Pharmaceuticals is a biotechnology company developing therapeutics for autoimmune and inflammatory diseases. The company focuses on protein-based drug candidates targeting conditions in immunology, with operations based in San Carlos, United States, and was founded in 2005.

Product overview

No information available about Alvine Pharmaceuticals products and services.

Differentiator

Problem solved

Functional benefit

Companies that use Alvine Pharmaceuticals

Customer profile

Ideal customer profiles1 record

Alvine Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Alvine Pharmaceuticals partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights2 records

Alvine Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Sanofi: Co-marketer of Dupixent, a flagship autoimmune/inflammation biologic. Comparable peer given its leadership position in immunology and ongoing M&A in the space.
  • AbbVie: Global immunology leader anchored by Humira and Skyrizi/Rinvoq. Comparable to Alvine as a major developer and commercializer of autoimmune/inflammatory therapeutics, though far broader in scope and scale.
  • Amgen: Large-cap biotech with a significant inflammation/autoimmune franchise (e.g., Enbrel, Otezla). Relevant incumbent peer given overlapping therapeutic focus and biologic modality.
  • Johnson & Johnson (Janssen): Janssen's immunology unit markets Stelara, Tremfya, and Remicade. Comparable as a leading commercializer of autoimmune biologics with deep pipeline investment.
  • Regeneron Pharmaceuticals: Developer of Dupixent and other inflammation biologics. Comparable as a biologics-driven company with a strong autoimmune/inflammation franchise and pipeline.
  • Bristol-Myers Squibb: Owns Zeposia and other immunology assets. Comparable as a major player with significant autoimmune/inflammation R&D and commercial presence.
  • Vertex Pharmaceuticals: Mid-to-large biotech expanding from cystic fibrosis into autoimmune and inflammatory diseases (e.g., VX-548, JAK programs). Comparable as a science-driven biotech with growing autoimmune ambitions.

Emerging players

  • AnaptysBio: Clinical-stage biotech developing antibody therapeutics for inflammation and autoimmune disease. Comparable as a focused autoimmune-focused biotech at a similar development stage.
  • ChemoCentryx: Autoimmune-focused biotech (acquired by Amgen in 2022) that developed Tavalisse and Tavneos. Comparable as a small-cap autoimmune specialist eventually absorbed by a larger player — a plausible Alvine outcome.
  • Protagonist Therapeutics: Clinical-stage biotech developing peptide-based therapeutics for autoimmune and inflammatory diseases. Comparable given similar size, modality innovation, and therapeutic area focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Alvine Pharmaceuticals social profiles

Digital presence

Alvine Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alvine Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

Alvine Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alvine Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alvine Pharmaceuticals

What does Alvine Pharmaceuticals do?

Alvine Pharmaceuticals is a biotechnology company developing therapeutics for autoimmune and inflammatory diseases. The company focuses on protein-based drug candidates targeting conditions in immunology, with operations based in San Carlos, United States, and was founded in 2005.

Is Alvine Pharmaceuticals a public or private company?

Alvine Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alvine Pharmaceuticals founded?

Alvine Pharmaceuticals was founded in 2005. It employs 11 to 50 people.

Where is Alvine Pharmaceuticals based?

Alvine Pharmaceuticals is headquartered in San Carlos, United States, in the North America region.

Who are Alvine Pharmaceuticals's main competitors?

Broad incumbents on record are Sanofi, AbbVie, Amgen, Johnson & Johnson (Janssen), Regeneron Pharmaceuticals, Bristol-Myers Squibb and Vertex Pharmaceuticals. Emerging players are AnaptysBio, ChemoCentryx and Protagonist Therapeutics.

Does Alvine Pharmaceuticals have an API?

No public API is recorded for Alvine Pharmaceuticals.

What industry is Alvine Pharmaceuticals in?

Alvine Pharmaceuticals's product category is Immunology Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals